Affymax (NASDAQ:AFFY) is one of today's notable stocks in decline, down 2.1% to $18.45. The S&P is trading lower by 1.1% to 1,404 and the Dow is trading 1.0% lower to 12,985.
Affymax Inc. is a clinical-stage biopharmaceutical company. The Company develops peptide-based drugs for the treatment of serious and life-threatening conditions such as kidney disease and cancer.
Affymax has overhead space with shares priced $18.45, or 42.3% below the average consensus analyst price target of $32.00. Affymax shares should encounter resistance at the 50-day moving average (MA) of $23.35 and support at its 200-day MA of $17.33.
Affymax share prices have moved between a 52-week high of $27.74 and a 52-week low of $6.35 and are now trading 191% above that low price at $18.45 per share. The 200-day and 50-day moving averages have moved 0.46% higher and 1.19% lower over the past week, respectively.